EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lipoprotein(a)—60 Years Later—What Do We Know?

Anna Pasławska, Przemysław J Tomasik iD

Cells · 2023

DOI: 10.3390/cells12202472 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Anna Pasławska und 1 weiteren Autor:innen. Beteiligte Einrichtung: Tuchow Health Center, Medical Hospital Laboratory, Szpitalna St. 1, 33-170 Tuchow, Poland. Hauptthemen laut MEDLINE: Atherosclerosis, Lipoprotein(a), Aortic Valve Stenosis. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipoprotein(a) (Lp(a)) molecule includes two protein components: apolipoprotein(a) and apoB100. The molecule is the main transporter of oxidized phospholipids (OxPL) in plasma. The concentration of this strongly atherogenic lipoprotein is predominantly regulated by the LPA gene expression. Lp(a) is regarded as a risk factor for several cardiovascular diseases. Numerous epidemiological, clinical and in vitro studies showed a strong association between increased Lp(a) and atherosclerotic cardiovascular disease (ASCVD), calcific aortic valve disease/aortic stenosis (CAVD/AS), stroke, heart failure or peripheral arterial disease (PAD). Although there are acknowledged contributions of Lp(a) to the mentioned diseases, clinicians struggle with many inconveniences such as a lack of well-established treatment lowering Lp(a), and common guidelines for diagnosing or assessing cardiovascular risk among both adult and pediatric patients. Lp(a) levels are different with regard to a particular race or ethnicity and might fluctuate during childhood. Furthermore, the lack of standardization of assays is an additional impediment. The review presents the recent knowledge on Lp(a) based on clinical and scientific research, but also highlights relevant aspects of future study directions that would approach more suitable and effective managing risk associated with increased Lp(a), as well as control the Lp(a) levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisLipoprotein(a)Aortic Valve StenosisRisk FactorsHumansAortic ValveCalcinosis

Stichwörter der Autor:innen

PCSK9 inhibitorantisense oligonucleotideapolipoprotein (a)cardiovascular diseasecoronary heart diseaselipoprotein (a)

Substanzen

Lipoprotein(a)

Autor:innen und Institutionen

  • Tuchow Health Center, Medical Hospital Laboratory, Szpitalna St. 1, 33-170 Tuchow, Poland.
  • Department of Clinical Biochemistry, Pediatric Institute, College of Medicine, Jagiellonian University, Wielicka St. 265, 30-663 Cracow, Poland.

ORCID-Profile: Przemysław J Tomasik

Zitieren

APA

Pasławska, A., & Tomasik, P. J. (2023). Lipoprotein(a)—60 Years Later—What Do We Know?. Cells. https://doi.org/10.3390/cells12202472

Vancouver

Pasławska A, Tomasik PJ. Lipoprotein(a)—60 Years Later—What Do We Know?. Cells. 2023. doi:10.3390/cells12202472

BibTeX
@article{Pasawska2023,
  author = {Pasławska, Anna and Tomasik, Przemysław J},
  title = {Lipoprotein(a)—60 Years Later—What Do We Know?},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12202472}
}
Kostenlos starten →